Search Results 741-750 of 17021 for monoclonal antibody
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.
... monoclonal antibody and an immunomodulatory drug. * Must be naïve to treatment with ABBV-383. Exclusion Criteria: - Received B-cell maturation antigen (BCMA) ...
... monoclonal antibodies, alpha-4 beta-7 integrin inhibiting monoclonal antibody, interleukin 12/23 inhibiting monoclonal antibody, JAK inhibitors.
* Any previous treatment with anti-CD19 antibody, complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody * ...
... monoclonal antibody (mAb). - Must be naïve to treatment with B-cell maturation antigen (BCMA)-targeted therapy. - Must be eligible to receive the ...
Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...
Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody ... Known hypersensitivity to multiple drugs, monoclonal antibodies or ...
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) ...
... monoclonal antibody. History of autoimmune or immune mediated disease prior to enrollment. Subjects with hypothyroidism, diabetes, adrenal insufficiency or ...
History of clinically significant hypersensitivity associated with monoclonal antibody therapies. 3. Personal history of venous or arterial thrombosis or ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.